hVIVO (LON:HVO) Posts Quarterly Earnings Results

hVIVO (LON:HVO) posted its quarterly earnings results on Tuesday. The company reported GBX (0.82) earnings per share (EPS) for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.

hVIVO Trading Down 1.3%

LON:HVO opened at GBX 5.83 on Thursday. hVIVO has a 1 year low of GBX 4.30 and a 1 year high of GBX 11. The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63. The stock has a fifty day moving average price of GBX 6.79 and a two-hundred day moving average price of GBX 7.39. The stock has a market capitalization of £40.10 million, a price-to-earnings ratio of -6.70 and a beta of 1.69.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.